MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$55,760K
EPS
-$0.82
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development-Related Party
911
1,982
5,549*
5,817
Research and development-Nonrelated Party
44,862
45,518
33,092*
27,158
General and administrative
14,178
12,742
8,127*
7,701
Total operating expenses
59,951
60,242
46,767
40,676
Loss from operations
-59,951
-60,242
-46,767*
-40,676
Interest income
4,576
4,083
4,269
4,386
Total other income
4,576
4,083
4,269*
4,386
Net loss before income taxes
-55,375
-56,159
-42,498*
-36,290
Income tax expense
61
52
79*
40
Net loss
-55,436
-56,211
-42,577*
-36,330
Unrealized loss on marketable securities, net of tax
-324
-486
651
-136
Total other comprehensive loss
-324
-486
651*
-136
Total comprehensive loss
-55,760
-56,697
-41,926
-36,466
Basic EPS
-0.82
-0.93
-0
-0.67
Diluted EPS
-0.82
-0.93
-0
-0.67
Basic Average Shares
67,925,963
60,717,041
163,921,584,906
54,563,864
Diluted Average Shares
67,925,963
60,717,041
163,921,584,906
54,563,864
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$55,760K
Net loss
-$55,436K
(-102.41%↓ Y/Y)
Total other
comprehensive loss
-$324K
Interest income
$4,576K
(-2.26%↓ Y/Y)
Net loss before
income taxes
-$55,375K
(-102.57%↓ Y/Y)
Income tax expense
$61K
(17.31%↑ Y/Y)
Unrealized loss on
marketable securities, net...
-$324K
Total other income
$4,576K
(-2.26%↓ Y/Y)
Loss from operations
-$59,951K
(-87.24%↓ Y/Y)
Total operating
expenses
$59,951K
(87.24%↑ Y/Y)
Research and
development-Nonrelated Party
$44,862K
(105.17%↑ Y/Y)
General and
administrative
$14,178K
(96.37%↑ Y/Y)
Research and
development-Related Party
$911K
(-68.93%↓ Y/Y)
Buy us a coffee
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)